Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection
Giovanbattista Ippoliti,1,2 Andrea Maria D'Armini,2 Marco Lucioni,3 Mazen Marjieh,1 Mario Viganò21UO Medicina Interna, Policlinico di Monza, Monza, Italy; 2Department of Surgical Sciences, Charles Dubost Transplant Center, Fondazione IRCCS San Matteo Hospital, 3Anatomic Pa...
Guardado en:
Autores principales: | Ippoliti G, D'Armini AM, Lucioni M, Marjieh M, Viganò M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/64eab19c9c1d493690ca47e1a28b6f7f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
por: Wojciechowski D, et al.
Publicado: (2012) -
Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response
por: Florian Terrec, et al.
Publicado: (2021) -
A RARE CASE: POSTTRANSPLANT NK/T CELL LYMPHOMA
por: Pınar Tığlıoğlu, et al.
Publicado: (2021) -
CHEMOKINE MARKERS ASSOCIATED WITH EARLY REJECTION OF KIDNEY ALLOGRAFT
por: T. V. Fedorenko, et al.
Publicado: (2019) -
Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy?
por: Kornerup LS, et al.
Publicado: (2019)